Evidence-informed guidance for the clinical use of oral semaglutide in obesity management - PubMed
4 hours ago
- #GLP-1 Agonist
- #Oral Semaglutide
- #Obesity Management
- Oral semaglutide is now approved for obesity management and cardiovascular risk reduction, offering weight loss comparable to subcutaneous GLP-1 therapies.
- Specific administration conditions are required: take the tablet first thing in the morning on an empty stomach with up to 120 mL of water, and wait 30 minutes before eating, drinking additional fluids, or taking other oral medications.
- Person-centered discussions before treatment are essential to set realistic expectations, ensure adherence, and manage potential adverse events.
- Clinical trials, including OASIS 4, show similar weight loss between oral and injectable semaglutide, with oral semaglutide designed to resist stomach acid for better absorption.
- Healthcare professionals should provide guidance on administration, discuss strategies for side effects, and help patients stay consistent with their treatment schedule.